Results from the phase 1b study of Orca-T with myeloblative chemotherapy conditioning showed the feasibility of the therapy in younger and older patients with hematologic malignancies.

Durable responses were seen with obecabtagene autoleucel in patients with relapsed/refractory B-cell acute lymphoblastic leukemia across bone marrow blast levels, with best efficacy and tolerability in those with less than 5% blasts.

Compared with CAR T-cell therapy, autologous hematopoietic cell transplantation resulted in lower relapse rates and improved progression-free survival in patients with relapsed large B-cell lymphoma while they were in complete response.

Orca-T, an allogeneic hematopoietic cell transplant biologic designed to control alloreactive immune responses, led to less graft-vs-host disease and favorable overall survival and relapse-free survival in patients with intermediate- and high-risk myelodysplastic syndrome.

Molecular minimal residual disease assessed after chemotherapy induction can identify patients with NPM1-mutated acute monocytic leukemia.

The JAK1 inhibitor golidocitinib led to responses in the challenging disease setting of relapsed/refractory peripheral T-cell lymphoma, as well as manageable hematologic toxicity, in the phase 2 JACKPOT8 study.

Results from the phase 3 ZUMA-7 trial showed superior progression-free survival and overall survival in patients 65 and older with large B-cell lymphoma with axicabtagene ciloleucel compared with standard of care.

Real-world evidence from over 2000 patients with chronic lymphocytic leukemia, over half of whom received prior covalent BTK inhibitor, confirmed the efficacy of venetoclax in pretreated patients.

Investigators in the MCARTY study reported safety and high response rates in a small number of patients with relapsed/refractory multiple myeloma who received chimeric antigen receptor T-cell therapy designed with a new process to target the D8 binder, meant to improve efficacy in targeting BCMA.

Updated results from the phase 1/2 BRUIN study show a high objective response rate and promising progression-free survival outcomes with pirtobrutinib following prior covalent Bruton tyrosine kinase inhibition in patients with chronic lymphocytic leukemia.

Four outpatient chimeric antigen receptor T-cell therapy programs utilized a virtual care program including remote patient monitoring following T-cell infusion, reducing hospital admissions and helping patients contact nurses during non-clinical hours.

According to extended follow-up of the phase 3 ALPINE trial, treatment with zanubrutinib continued to demonstrate improved progression-free survival in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Cyrus M. Khan, MD, and participants discussed the case of a patient with diffuse large B-cell lymphoma who progressed after complete remission on standard-of-care frontline therapy, then had stable disease after receiving polatuzumab vedotin, bendamustine, and rituximab.

Although the use of bridging therapy prior to treatment with axicabtagene ciloleucel did not improve efficacy or safety outcomes for patients with relapsed/refractory large B-cell lymphoma, responses to bridging therapy may be prognostic of favorable outcomes after axi-cel administration.

Brexucabtagene autoleucel is safe and effective in real-world patients with relapsed/refractory mantle cell lymphoma, regardless of the presence of high-risk features.

Results from the phase 1/2 SAVE trial demonstrated an improved objective response rate when revumenib was added to decitabine/cedazuridine, and venetoclax for patients with relapsed/refractory acute myeloid leukemia.

A machine learning, artificial intelligence algorithm analyzing diagnostic bone marrow biopsy digital whole-slide images was able to effectively differentiate with 92.3% accuracy between prefibrotic primary myelofibrosis and essential thrombocythemia.

Treatment with an all-oral regimen of arsenic trioxide, all-trans retinoic acid, and ascorbic acid led to both 3-year overall survival and relapse-free survival rates of 97% in patients with acute promyelocytic leukemia.

Idecabtagene vicleucel improved health-related quality of life compared with standard regimens in patients with triple-class exposed, relapsed/refractory multiple myeloma.

The retrospective analysis demonstrated comparable outcomes with teclistamab from the phase 2 MajesTEC-1 trial, highlighting the need for close monitoring and supportive care in patients treated for their relapsed or refractory multiple myeloma.

Neoadjuvant nivolumab and non–anthracycline containing chemotherapy produced promising pathologic complete response rates regardless of whether nivolumab was administered before or during treatment with carboplatin and paclitaxel in patients with stage I to IIB triple-negative breast cancer.

Findings from the ADAPTcycle trial suggest that endocrine therapy plus ovarian suppression can generate high response rates in patients with hormone receptor-positive early breast cancer, regardless of age.

Neoadjuvant pembrolizumab combined with chemotherapy followed by adjuvant pembrolizumab compared with placebo plus chemotherapy continued to show a clinically meaningful improvement in event-free survival in patients with high-risk, early-stage triple-negative breast cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Herbert A. Eradat, MD, reviewed data supporting the use of zanubrutinib and acalabrutinib in treatment of relapsed/refractory chronic lymphocytic leukemia.